In the target population, do patients with BRCA1/2 mutation (somatic or germline mutation) or homologous-recombination deficiency (HRD) have different optimal regimens for maintenance therapy and outcomes compared with patients without BRCA 1/2 mutation or HRD? This evidence concerns the gene BRCA1 and hypoparathyroidism-retardation-dysmorphism syndrome.